Elicio Therapeutics (ELTX) Other Working Capital Changes (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Other Working Capital Changes came in at -$240000.0 in Q1 2026, up 50.92% YoY from -$159024.4 in Q1 2025, and up 52.0% on a QoQ basis from -$500000.0 in Q4 2025.
Elicio Therapeutics (ELTX) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Other Working Capital Changes data on file, last reported at -$240000.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 50.92% year-over-year to -$240000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$920000.0 (up 20.42% YoY) and the FY2025 annual result came in at -$1.2 million, down 28.32% from the prior year.
- Other Working Capital Changes advanced to -$240000.0 in Q1 2026, from -$500000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $1.5 million in Q1 2022 to a low of -$1.5 million in Q2 2022.
- A 5-year average of $72588.2 and a median of $344000.0 in 2025 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2023 — Other Working Capital Changes soared 324.34% — and 2024, when it plunged 543.04%.
- Tracing ELTX's Other Working Capital Changes over 5 years: stood at -$157000.0 in 2022, then sank by 50.96% to -$237000.0 in 2023, then sank by 543.04% to -$1.5 million in 2024, then surged by 67.19% to -$500000.0 in 2025, then surged by 52.0% to -$240000.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$240000.0 (Q1 2026), -$500000.0 (Q4 2025), and -$228000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.53 Bn | 130.68 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.34 Bn | 78.35 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.67 Bn | 59.48 Bn | 1.37 Bn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.94 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.78 Bn | 27.47 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.81 Bn | 9.42 Bn | 668.28 Mn |
| 8 | Insmed | 27.21 Bn | 26.05 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 26.99 Bn | 26.15 Bn | - |
| 10 | Elicio Therapeutics | 59.56 Mn | 36.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 753,000.00 |
| Jun 30, 2026 | 753,000.00 |
| Jun 30, 2026 | 753,000.00 |
| Mar 31, 2026 | 504,000.00 |
| Mar 31, 2026 | 504,000.00 |
| Mar 31, 2026 | 504,000.00 |
| Dec 31, 2025 | -106,000.00 |
| Dec 31, 2025 | -106,000.00 |
| Dec 31, 2025 | -106,000.00 |
| Sep 30, 2025 | 344,000.00 |
| Sep 30, 2025 | 344,000.00 |
| Sep 30, 2025 | 344,000.00 |
| Jun 30, 2025 | -1.39 Mn |
| Jun 30, 2025 | -1.39 Mn |
| Jun 30, 2025 | -1.39 Mn |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | -1.42 Mn |
| Dec 31, 2024 | -1.42 Mn |